Apr 10, 2026
Tempus AI (TEM) Stock Surges on Expanded Gilead Partnership for Oncology Data Platform
Tempus AI (TEM) stock gains as Gilead partnership expands AI oncology data access. Diagnostics revenue jumps 111% with contract backlog exceeding $1.1B.
The post Tempus AI (TEM) Stock Surges on Expanded Gilead Partnership for Oncology Data Platform appeared first on Blockonomi.
Source: Blockonomi →Related News
- 7 hours ago
Apple (AAPL) Stock: Q2 Earnings Beat Expectations with 17% Revenue Jump and $100...
- 10 hours ago
Alphabet (GOOGL) Stock Soars 10% as Q1 Results Demolish Analyst Projections
- 10 hours ago
Amazon (AMZN) Stock Dips After Strong Q1 Earnings — What Spooked Investors?
- 10 hours ago
CoreWeave (CRWV) Stock Climbs 8% Despite $45M Insider Share Dump
- 10 hours ago
Nvidia (NVDA) Tumbles 4% Amid Rising Competition from Google and Amazon Custom C...